Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that targets the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA) and the CD3 antigen on T lymphocytes. It demonstrates significant antitumor activity and high efficacy in patients with late-stage relapsed/refractory multiple myeloma (RRMM). MW: 145.78 KD.